{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T21:44:01Z","timestamp":1768686241945,"version":"3.49.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s11940-019-0596-8","type":"journal-article","created":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T07:02:57Z","timestamp":1573282977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Therapies for Restless Legs in Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"21","author":[{"given":"Val\u00e9rie","family":"Cochen De Cock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,9]]},"reference":[{"key":"596_CR1","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.sleep.2014.03.025","volume":"15","author":"RP Allen","year":"2014","unstructured":"Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndrome\/Willis-Ekbom disease diagnostic criteria: Updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria - history, rationale, description, and significance. Sleep Med. 2014;15:860\u201373.","journal-title":"Sleep Med"},{"key":"596_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"596_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ane.12307","volume":"13","author":"SM Fereshtehnejad","year":"2015","unstructured":"Fereshtehnejad SM, Shafieesabet M, Shahidi GA, Delbari A, L\u00f6kk J. Restless legs syndrome in patients with Parkinson\u2019s disease: a comparative study on prevalence, clinical characteristics, quality of life and nutritional status. Acta Neurol Scand. 2015;13:211\u20138.","journal-title":"Acta Neurol Scand"},{"key":"596_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.parkreldis.2012.12.005","volume":"19","author":"K Bhalsing","year":"2013","unstructured":"Bhalsing K, Suresh K, Muthane UB, Pal PK. Prevalence and profile of restless legs syndrome in Parkinson\u2019s disease and other neurodegenerative disorders: a case-control study. Parkinsonism Relat Disord. 2013;19:426\u201330.","journal-title":"Parkinsonism Relat Disord"},{"key":"596_CR5","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/S1353-8020(13)70004-X","volume":"20","author":"RM Rijsman","year":"2014","unstructured":"Rijsman RM, Schoolderman LF, Rundervoort R, Louter M. Restless legs syndrome in Parkinson\u2019s disease. Park Relat Disord. 2014;20:S5\u20139.","journal-title":"Park Relat Disord."},{"key":"596_CR6","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1002\/mds.22694","volume":"24","author":"CM Peralta","year":"2009","unstructured":"Peralta CM, Frauscher B, Seppi K, Wolf E, Wenning GK, H\u00f6gl B, et al. Restless legs syndrome in Parkinson\u2019s disease. Mov Disord. 2009;24:2076\u201380.","journal-title":"Mov Disord"},{"key":"596_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.smrv.2006.01.001","volume":"10","author":"D Garcia-Borreguero","year":"2006","unstructured":"Garcia-Borreguero D, Egatz R, Winkelmann J, Berger K. Epidemiology of restless legs syndrome: the current status. Sleep Med Rev. 2006;10:153\u201367.","journal-title":"Sleep Med Rev"},{"key":"596_CR8","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","volume":"13","author":"RP Allen","year":"2005","unstructured":"Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;13:1286\u201392.","journal-title":"Arch Intern Med"},{"key":"596_CR9","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1212\/WNL.0000000000002542","volume":"86","author":"C Trenkwalder","year":"2016","unstructured":"Trenkwalder C, Allen R, Hogl B, Paulus W, Winkelmann J. Restless legs syndrome associated with major diseases a systematic review and new concept. Neurology. 2016;86:1336\u201343.","journal-title":"Neurology."},{"key":"596_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/sleep\/23.3.1c","volume":"23","author":"TC Wetter","year":"2000","unstructured":"Wetter TC, Collado-Seidel V, Pollm\u00e4cher T, Yassouridis A, Trenkwalder C. Sleep and periodic leg movement patterns in drug-free patients with Parkinson\u2019s disease and multiple system atrophy. Sleep. 2000;23:361\u20137.","journal-title":"Sleep."},{"key":"596_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/mds.870120111","volume":"12","author":"J Montplaisir","year":"1997","unstructured":"Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesp\u00e9rance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12:61\u20135.","journal-title":"Mov Disord"},{"key":"596_CR12","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/mds.20042","volume":"19","author":"SJ Pittock","year":"2004","unstructured":"Pittock SJ, Parrett T, Adler CH, Parisi JE, Dickson DW, Ahlskog JE. Neuropathology of primary restless leg syndrome: absence of specific tau- and alpha-synuclein pathology. Mov Disord. 2004;19:695\u20139.","journal-title":"Mov Disord"},{"key":"596_CR13","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.sleep.2014.05.009","volume":"15","author":"CJ Earley","year":"2014","unstructured":"Earley CJ, Connor J, Garcia-Borreguero D, Jenner P, Winkelman J, Zee PC, et al. Altered brain iron homeostasis and dopaminergic function in restless legs syndrome (Willis-Ekbom disease). Sleep Med. 2014;15:1288\u2013301.","journal-title":"Sleep Med"},{"key":"596_CR14","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1093\/brain\/awp125","volume":"132","author":"JR Connor","year":"2009","unstructured":"Connor JR, Wang XS, Allen RP, Beard JL, Wiesinger JA, Felt BT, et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain. 2009;132:2403\u201312.","journal-title":"Brain."},{"key":"596_CR15","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1212\/01.WNL.0000123251.60485.AC","volume":"11","author":"JR Connor","year":"2004","unstructured":"Connor JR, Wang XS, Patton SM, Menzies SL, Troncoso JC, Earley CJ, et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology. 2004;11:1563\u20137.","journal-title":"Neurology."},{"key":"596_CR16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1212\/01.WNL.0000078887.16593.12","volume":"16","author":"JR Connor","year":"2003","unstructured":"Connor JR, Boyer PJ, Menzies SL, Dellinger B, Allen RP, Ondo WG, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology. 2003;16:304\u20139.","journal-title":"Neurology."},{"key":"596_CR17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.parkreldis.2015.03.010","volume":"21","author":"Z Gan-Or","year":"2015","unstructured":"Gan-Or Z, Alcalay RN, Bar-Shira A, Leblond CS, Postuma RB, Ben-Shachar S, et al. Genetic markers of restless legs syndrome in Parkinson disease. Park Relat Disord. 2015;21:582\u20135.","journal-title":"Park Relat Disord"},{"key":"596_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1212\/01.wnl.0000317101.67684.e3","volume":"71","author":"C Vilari\u00f1o-G\u00fcell","year":"2008","unstructured":"Vilari\u00f1o-G\u00fcell C, Soto AI, Young JE, Lin SC, Uitti RJ, Wszolek ZK, et al. Susceptibility genes for restless legs syndrome are not associated with Parkinson disease. Neurology. 2008;71:222\u20133.","journal-title":"Neurology."},{"key":"596_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1389-9457(02)00258-7","volume":"4","author":"AS Walters","year":"2003","unstructured":"Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4:121\u201332.","journal-title":"Sleep Med"},{"key":"596_CR20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/mds.23476","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kohnen R, H\u00f6gl B, Metta V, Sixel-D\u00f6ring F, Frauscher B, et al. Parkinson\u2019s disease sleep scale-validation of the revised version PDSS-2. Mov Disord. 2011;26:644\u201352.","journal-title":"Mov Disord"},{"key":"596_CR21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/mds.24969","volume":"27","author":"VC De Cock","year":"2012","unstructured":"De Cock VC, Bayard S, Yu H, Grini M, Carlander B, Postuma R, et al. Suggested immobilization test for diagnosis of restless legs syndrome in Parkinson\u2019s disease. Mov Disord. 2012;27:743\u20139.","journal-title":"Mov Disord"},{"key":"596_CR22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/JCP.0b013e318272cdd8","volume":"32","author":"S Perez-Lloret","year":"2012","unstructured":"Perez-Lloret S, Rey M, Bondon-Guitton E, Rascol O, Montastruc JL. Drugs associated with restless legs syndrome: a case\/noncase study in the French pharmacovigilance database. J Clin Psychopharmacol. 2012;32:824\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"596_CR23","first-page":"42","volume":"16","author":"G Loddo","year":"2017","unstructured":"Loddo G, Calandra-Buonaura G, Sambati L, Giannini G, Cecere A, Cortelli P, et al. The treatment of sleep disorders in Parkinson\u2019s disease: from research to clinical practice. Front Neurol. 2017;16:42.","journal-title":"Front Neurol"},{"key":"596_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.sleep.2016.01.017","volume":"21","author":"D Garcia-Borreguero","year":"2016","unstructured":"Garcia-Borreguero D, Silber M, Winkelman JW, Hogl B, Bainbridge J, Buchfuhrer M. Guidelines for the first-line treatment of restless legs syndrome\/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1\u201311.","journal-title":"Sleep Med"},{"key":"596_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12883-015-0331-3","volume":"15","author":"G Grolez","year":"2015","unstructured":"Grolez G, Moreau C, Sablonni\u00e8re B, Gar\u00e7on G, Devedjian JC, Meguig S, et al. Ceruloplasmin activity and iron chelation treatment of patients with Parkinson\u2019s disease. BMC Neurol. 2015;15:74.","journal-title":"BMC Neurol"},{"key":"596_CR26","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/mds.27260","volume":"33","author":"J Winkelmann","year":"2018","unstructured":"\u2022\u2022 Winkelmann J, Allen RP, H\u00f6gl B, Inoue Y, Oertel W, Salminen AV, et al. Treatment of restless legs syndrome: evidence-based review and implications for clinical practice (revised 2017). Mov Disord. 2018;33:1077\u201391. The newest evidence-based review on the treatment of idiopathic RLS.","journal-title":"Mov Disord"},{"key":"596_CR27","first-page":"S304Poster953","volume":"31","author":"J Perez-Perez","year":"2016","unstructured":"Perez-Perez J, Pascual-Sedano B, Campolongo A, Kulisevsky J. Duodopa for the treatment of severe restless legs syndrome. Mov Disord. 2016;31:S304Poster953.","journal-title":"Mov Disord"},{"key":"596_CR28","first-page":"1315","volume":"2015","author":"J Pagonabarraga","year":"2015","unstructured":"Pagonabarraga J, Pi\u00f1ol G, Cardozo A, Sanz P, Puente V, Oterm\u00edn P, et al. Transdermal rotigotine improves sleep fragmentation in parkinson\u2019s disease: results of the multicenter, prospective SLEEP-FRAM study. Parkinsons Dis. 2015;2015:1315\u20138.","journal-title":"Parkinsons Dis"},{"key":"596_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12883-015-0267-7","volume":"15","author":"J Kim","year":"2015","unstructured":"Kim J, Chung S, Kim J, Jeon B, Singh P, Thierfelder S, et al. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson\u2019s disease: an open-label study. BMC Neurol. 2015;15:17.","journal-title":"BMC Neurol"},{"key":"596_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/475630","volume":"2015","author":"Francesc Vallderiola","year":"2015","unstructured":"Vallderiola F, Compta Y, Aparicio J, Tarradellas J, Salazar G, Oliver J, et al. Effects of night-time use of rotigotine on nocturnal symptoms in Parkinson\u2019s disease. Parkinsons Dis. 2015;2015:475630.","journal-title":"Parkinson's Disease"},{"key":"596_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11325-016-1414-0","volume":"21","author":"Y Wang","year":"2017","unstructured":"Wang Y, Yang YC, Lan DM, Wu HJ, Zhao ZX. An observational clinical and video-polysomnographic study of the effects of rotigotine in sleep disorder in Parkinson\u2019s disease. Sleep Breath. 2017;21:319\u201325.","journal-title":"Sleep Breath"},{"key":"596_CR32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26:90\u20139 The only randomized double blind study on the efficacy of a treatment in RLS with PD.","journal-title":"Mov Disord"},{"key":"596_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1600-0404.1999.tb00732.x","volume":"100","author":"I Reuter","year":"2009","unstructured":"Reuter I, Ellis CM, Chaudhuri KR. Nocturnal subcutaneous apomorphine infusion in Parkinson\u2019s disease and restless legs syndrome. Acta Neurol Scand. 2009;100:163\u20137.","journal-title":"Acta Neurol Scand"},{"key":"596_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10072-003-0133-z","volume":"24","author":"L Priano","year":"2003","unstructured":"Priano L, Albani G, Brioschi A, Guastamacchia G, Calderoni S, Lopiano L, et al. Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment. Neurol Sci. 2003;24:207\u20138.","journal-title":"Neurol Sci"},{"key":"596_CR35","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1111\/ene.13449","volume":"24","author":"IH Iftikhar","year":"2017","unstructured":"Iftikhar IH, Alghothani L, Trotti LM. Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis. Eur J Neurol. 2017;24:1446\u201356.","journal-title":"Eur J Neurol"},{"key":"596_CR36","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2147\/JPR.S102696","volume":"9","author":"B Parsons","year":"2016","unstructured":"Parsons B, Argoff CE, Clair A, Emir B. Improvement in pain severity category in clinical trials of pregabalin. J Pain Res. 2016;9:779\u201385.","journal-title":"J Pain Res"},{"key":"596_CR37","first-page":"1","volume":"10","author":"WH Jost","year":"2019","unstructured":"Jost WH, Buhmann C. The challenge of pain in the pharmacological management of Parkinson\u2019s disease. Expert Opin Pharmacother. 2019;10:1\u20138.","journal-title":"Expert Opin Pharmacother"},{"key":"596_CR38","doi-asserted-by":"publisher","first-page":"e107278","DOI":"10.1371\/journal.pone.0107278","volume":"9","author":"V Cochen De Cock","year":"2014","unstructured":"Cochen De Cock V, Bayard S, Jaussent I, Charif M, Grini M, Croisier Langenier M, et al. Daytime sleepiness in Parkinson\u2019s disease: a reappraisal. PLoS One. 2014;9:e107278.","journal-title":"PLoS One"},{"key":"596_CR39","first-page":"82","volume":"48","author":"D Garcia-Borreguero","year":"2002","unstructured":"Garcia-Borreguero D, Larrosa O, De la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002;48:82\u20136.","journal-title":"Neurology."},{"key":"596_CR40","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1303646","volume":"370","author":"RP Allen","year":"2014","unstructured":"Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014;370:621\u201331.","journal-title":"N Engl J Med"},{"key":"596_CR41","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.sleep.2010.03.003","volume":"11","author":"R Allen","year":"2010","unstructured":"Allen R, Chen C, Soaita A, Wohlberg C, Knapp L, Peterson BT, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. 2010;11:512\u20139.","journal-title":"Sleep Med"},{"key":"596_CR42","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1212\/WNL.0b013e3181e1ce73","volume":"74","author":"D Garcia-Borreguero","year":"2010","unstructured":"Garcia-Borreguero D, Larrosa O, Williams AM, Albares J, Pascual M, Palacios JC, et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology. 2010;74:1897\u2013904.","journal-title":"Neurology."},{"key":"596_CR43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/WNF.0b013e3181a9eb1b","volume":"32","author":"S Perez Lloret","year":"2009","unstructured":"Perez Lloret S, Amaya M, Merello M. Pregabalin-induced parkinsonism: a case report. Clin Neuropharmacol. 2009;32:353\u20134.","journal-title":"Clin Neuropharmacol"},{"key":"596_CR44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.clineuro.2008.11.015","volume":"111","author":"C Erol","year":"2009","unstructured":"Erol C, Ozben S, Ozer F, Cetin S, Tiras R. Bilateral ballism induced by gabapentin in idiopatic Parkinson\u2019s disease. Clin Neurol Neurosurg. 2009;111:397.","journal-title":"Clin Neurol Neurosurg"},{"key":"596_CR45","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/mds.21209","volume":"15","author":"PM Raju","year":"2007","unstructured":"Raju PM, Walker RW, Lee MA. Dyskinesia induced by gabapentin in idiopathic Parkinson\u2019s disease. Mov Disord. 2007;15:288\u20139.","journal-title":"Mov Disord"},{"key":"596_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1185\/03007995.2012.746217","volume":"29","author":"Y Inoue","year":"2013","unstructured":"Inoue Y, Hirata K, Uchimura N, Kuroda K, Hattori N, Takeuchi M. Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Curr Med Res Opin. 2013;29:13\u201321.","journal-title":"Curr Med Res Opin"},{"key":"596_CR47","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/WNF.0b013e318259eac8","volume":"35","author":"R Lal","year":"2012","unstructured":"Lal R, Ellenbogen A, Chen D, Zomorodi K, Atluri H, Luo W, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol. 2012;35:165\u201373.","journal-title":"Clin Neuropharmacol"},{"key":"596_CR48","doi-asserted-by":"crossref","unstructured":"Lee D, Ziman R, Perkins A, Poceta J, Walters A, Barrett R. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7:282\u201392.","DOI":"10.5664\/JCSM.1074"},{"key":"596_CR49","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/WNF.0b013e3181b3ab16","volume":"32","author":"AS Walters","year":"2009","unstructured":"Walters AS, Ondo WG, Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, et al. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2009;32:311\u201320.","journal-title":"Clin Neuropharmacol"},{"key":"596_CR50","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/sleep\/32.2.159","volume":"32","author":"CA Kushida","year":"2009","unstructured":"Kushida CA, Walters AS, Becker P, Thein SG, Perkins AT, Roth T, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512\/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep. 2009;32:159\u201368.","journal-title":"Sleep."},{"key":"596_CR51","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1212\/01.wnl.0000341770.91926.cc","volume":"72","author":"C Kushida","year":"2009","unstructured":"Kushida C, Becker P, Ellenbogen A, Canafax D, Barrett R. Randomized, double-blind, placebo-controlled study of XP13512\/GSK1838262 in patients with RLS. Neurology. 2009;72:439\u201349.","journal-title":"Neurology."},{"key":"596_CR52","doi-asserted-by":"publisher","first-page":"512","DOI":"10.4065\/mcp.2009.0700","volume":"85","author":"R Bogan","year":"2010","unstructured":"Bogan R, Bornemann M, Kushida C, Tran P, Barrett R. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc. 2010;85:512\u201321.","journal-title":"Mayo Clin Proc"},{"key":"596_CR53","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/psyg.12043","volume":"14","author":"H Fujishiro","year":"2014","unstructured":"Fujishiro H. Effects of gabapentin enacarbil on restless legs syndrome and leg pain in dementia with Lewy bodies. Psychogeriatrics. 2014;14:132\u20134.","journal-title":"Psychogeriatrics."},{"key":"596_CR54","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/sleep\/16.4.327","volume":"16","author":"AS Walters","year":"1993","unstructured":"Walters AS, Wagner ML, Hening WA, Grasing K, Mills R, Chokroverty S, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep. 1993;16:327\u201332.","journal-title":"Sleep."},{"key":"596_CR55","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S1474-4422(13)70239-4","volume":"12","author":"C Trenkwalder","year":"2013","unstructured":"Trenkwalder C, Bene\u0161 H, Grote L, Garc\u00eda-Borreguero D, H\u00f6gl B, Hopp M, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12:1141\u201350.","journal-title":"Lancet Neurol"},{"key":"596_CR56","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/S1474-4422(15)00243-4","volume":"14","author":"C Trenkwalder","year":"2015","unstructured":"Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vali\u0161 M, et al. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson\u2019s disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2015;14:1161\u201370.","journal-title":"Lancet Neurol"},{"key":"596_CR57","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.mayocp.2017.11.007","volume":"93","author":"MH Silber","year":"2018","unstructured":"Silber MH, Becker PM, Buchfuhrer MJ, Earley CJ, Ondo WG, Walters AS, et al. The appropriate use of opioids in the treatment of refractory restless legs syndrome. Mayo Clin Proc. 2018;93:59\u201367.","journal-title":"Mayo Clin Proc"},{"key":"596_CR58","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.sleep.2006.05.011","volume":"7","author":"CJ Earley","year":"2006","unstructured":"Earley CJ, Allen RP. Restless legs syndrome augmentation associated with tramadol. Sleep Med. 2006;7:592\u20133.","journal-title":"Sleep Med"},{"key":"596_CR59","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/mds.21342","volume":"22","author":"R Vetrugno","year":"2007","unstructured":"Vetrugno R, La Morgia C, D\u2019Angelo R, Loi D, Provini F, Plazzi G, et al. Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord. 2007;22:424\u20137.","journal-title":"Mov Disord"},{"key":"596_CR60","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.sleep.2015.08.005","volume":"16","author":"S Chokroverty","year":"2015","unstructured":"Chokroverty S. Opioid-induced hyperalgesia and dopamine-induced augmentation in an intractable and refractory case of RLS. Sleep Med. 2015;16:1304.","journal-title":"Sleep Med"},{"key":"596_CR61","first-page":"CD006939","volume":"3","author":"K Carlos","year":"2017","unstructured":"Carlos K, Prado GF, Teixeira CDM, Conti C, de Oliveira MM, Prado LBF, et al. Benzodiazepines for restless legs syndrome. Cochrane Database Syst Rev. 2017;3:CD006939.","journal-title":"Cochrane Database Syst Rev"},{"key":"596_CR62","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/mds.21002","volume":"21","author":"I Shpirer","year":"2006","unstructured":"Shpirer I, Miniovitz A, Klein C, Goldstein R, Prokhorov T, Theitler J, et al. Excessive daytime sleepiness in patients with parkinson\u2019s disease: a polysomnography study. Mov Disord. 2006;21:1432\u20138.","journal-title":"Mov Disord"},{"key":"596_CR63","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1474-4422(08)70291-6","volume":"8","author":"AL Benabid","year":"2009","unstructured":"Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson\u2019s disease. Lancet Neurol [Internet]. 2009;8:67\u201381.Available from:. \nhttps:\/\/doi.org\/10.1016\/S1474-4422(08)70291-6\n\n.","journal-title":"Lancet Neurol [Internet]"},{"issue":"3","key":"596_CR64","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.parkreldis.2010.11.017","volume":"17","author":"L.M. Chahine","year":"2011","unstructured":"Chahine LM, Ahmed A, Sun Z. Effects of STN DBS for Parkinson\u2019s disease on restless legs syndrome and other sleep-related measures. Park Relat Disord. 2011;17:208\u201311.","journal-title":"Parkinsonism & Related Disorders"},{"key":"596_CR65","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/mds.20911","volume":"21","author":"E Driver-Dunckley","year":"2006","unstructured":"Driver-Dunckley E, Evidenter VGH, Adler CH, Hillman R, Hernandez J, Fletcher G, et al. Restless legs syndrome in Parkinson\u2019s disease patients may improve with subthalamic stimulation. Mov Disord. 2006;21:1287\u20139.","journal-title":"Mov Disord"},{"key":"596_CR66","first-page":"e1013","volume":"91","author":"O Klepitskaya","year":"2017","unstructured":"Klepitskaya O, Liu Y, Tsai J. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) improves restless leg syndrome (RLS) in patients with Parkinson disease (PD). Mov Disord. 2017;91:e1013\u201321.","journal-title":"Mov Disord"},{"key":"596_CR67","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1212\/01.WNL.0000147288.26029.B8","volume":"63","author":"S Kedia","year":"2004","unstructured":"Kedia S, Moro E, Tagliati M, Lang AE, Kumar R. Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. Neurology. 2004;63:2410\u20132.","journal-title":"Neurology."},{"key":"596_CR68","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.sleep.2014.11.020","volume":"16","author":"A Marques","year":"2015","unstructured":"Marques A, Fantini ML, Morand D, Pereira B, Derost P, Ulla M, et al. Emergence of restless legs syndrome after subthalamic stimulation in Parkinson\u2019s disease: a dopaminergic overstimulation? Sleep Med. 2015;16:583\u20138 Interesting discussion on the mechanism of RLS and its improvement by DBS.","journal-title":"Sleep Med"},{"key":"596_CR69","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/1531-8249(199911)46:5<800::AID-ANA22>3.0.CO;2-F","volume":"46","author":"D Rye","year":"1999","unstructured":"Rye D, DeLong M. Amelioration of sensory limb discomfort of restless legs syndrome by pallidotomy. Ann Neurol. 1999;46:800\u20131.","journal-title":"Ann Neurol"},{"key":"596_CR70","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/jnr.21207","volume":"85","author":"H Zhao","year":"2007","unstructured":"Zhao H, Zhu W, Pan T, Xie W, Zhang A, Ondo WG, et al. Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation. J Neurosci Res. 2007;85:1065\u201376.","journal-title":"J Neurosci Res"},{"key":"596_CR71","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.20349","volume":"20","author":"MS Okun","year":"2005","unstructured":"Okun MS, Fernandez HH, Foote KD. Deep brain stimulation of the GPi treats restless legs syndrome associated with dystonia. Mov Disord. 2005;20:500\u20131.","journal-title":"Mov Disord"},{"key":"596_CR72","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S0166-2236(02)02181-1","volume":"25","author":"R de la Fuente-Fernandez","year":"2002","unstructured":"de la Fuente-Fernandez R, Stoessl AJ. The placebo effect in Parkinson\u2019s disease. Trends Neurosci. 2002;25:302\u20136.","journal-title":"Trends Neurosci"},{"key":"596_CR73","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/brain\/awm244","volume":"13","author":"S Fulda","year":"2008","unstructured":"Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain. 2008;13:902\u201317.","journal-title":"Brain."},{"key":"596_CR74","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1126\/science.1060937","volume":"293","author":"R De la Fuente-Fern\u00e1ndez","year":"2001","unstructured":"De la Fuente-Fern\u00e1ndez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson\u2019s disease. Science. 2001;293:1164\u20136.","journal-title":"Science"},{"key":"596_CR75","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1378\/chest.08-1665","volume":"135","author":"CJ Lettieri","year":"2009","unstructured":"Lettieri CJ, Eliasson AH. Pneumatic compression devices are an effective therapy for restless legs syndrome: a prospective, randomized, double-blinded, sham-controlled trial. Chest. 2009;135:74\u201380. The only randomized study on a non-drug therapy of idiopathic RLS.","journal-title":"Chest."}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-019-0596-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-019-0596-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-019-0596-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T01:20:34Z","timestamp":1604798434000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-019-0596-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":75,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["596"],"URL":"https:\/\/doi.org\/10.1007\/s11940-019-0596-8","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"9 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The author declares that she has no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"56"}}